Olga Urazova

Prof. Dr. Olga Urazova

Siberian State Medical University
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
Daria Shunkina (Skuratovskaia)Daria Shunkina (Skuratovskaia)
Daria Shunkina (Skuratovskaia)
MVMaria Vulf
Maria Vulf
OKOlga Khaziakhmatova
Olga Khaziakhmatova
VMVladimir Malashchenko
Vladimir Malashchenko
AKAleksandra Komar
Aleksandra Komar
LLLarisa Litvinova
Larisa Litvinova
Chronic inflammation may not begin with local tissue disorders, such as hypoxia, but with the accumulation of critically activated macrophages in one site. The purpose of this review is to analyze the data reported in the scientific literature on the features of the functions of macrophages and their contributions to the development of pathology in various tissues during aseptic inflammation in obese subjects. In individuals with obesity, increased migration of monocytes from the peripheral blood to various tissues, the proliferation of resident macrophages and a change in the balance between alternatively activated anti-inflammatory macrophages (M2) and pro-inflammatory classically activated macrophages (M1) towards the latter have been observed. The primary cause of some metabolic pathologies has been precisely identified as the recruitment of macrophages with an altered phenotype, which is probably typical for many other pathologies. Recent studies have identified phenotypes, such as metabolically activated M (MMe), oxidized (Mox), hemoglobin-related macrophages (Mhem and MHb), M4 and neuroimmunological macrophages (NAM, SAM), which directly and indirectly affect energy metabolism. The high heterogeneity of macrophages in tissues contributes to the involvement of these cells in the development of a wide range of immune responses, including pathological ones. The replenishment of tissue-specific macrophages occurs at the expense of infiltrating monocyte-derived macrophages (MoMFs) in the pathological process. The origin of MoMFs from a general precursor retains their common regulatory mechanisms and similar sensitivity to regulatory stimuli. This makes it possible to find universal approaches to the effect on these cells and, as a consequence, universal approaches for the treatment of various pathological conditions.

1 August 2009 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
INI. O. Naslednikova
I. O. Naslednikova
OUOlga Urazova
Olga Urazova
OVO. V. Voronkova
O. V. Voronkova
ASA. K. Strelis
A. K. Strelis
VNV. V. Novitsky
V. V. Novitsky
TFT. V. Fedorovich
T. V. Fedorovich

1 April 2014 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
TKT. E. Kononova
T. E. Kononova
OUOlga Urazova
Olga Urazova
VNV. V. Novitskii
V. V. Novitskii
ECE. G. Churina
E. G. Churina
YKYu. V. Kolobovnikova
Yu. V. Kolobovnikova
OPO. V. Pechenova
O. V. Pechenova

1 April 2021 in IJC Heart & Vasculature
Verified
Journal Article
Open access
SPSvetlana P. PETROVNA
Svetlana P. PETROVNA
OUOlga Urazova
Olga Urazova
VSVladimir M. Shipulin
Vladimir M. Shipulin
MVM. Vins
M. Vins
APA. Pryakhin
A. Pryakhin
VNV. Novitskiy
V. Novitskiy
To identify an imbalance of cardiac remodeling mediators and monocytes subpopulation in blood, distribution of myocardium macrophages in patients with ischemic cardiomyopathy (ICMP). The study engaged 30 patients with ICMP, 26 patients with coronary heart disease (CHD) without ICMP, 15 healthy donors. Concentrations of TGFβ, MMP-9, MCP-1, galectin-3 were measured in plasma of blood from the coronary sinus and peripheral blood in CHD patients, as well as in peripheral blood in healthy donors, by enzyme immunoassay method. The ration of classical, intermediate, non-classical, transitional monocytes in peripheral blood of patients and healthy donors was assessed by flow cytometry (expression CD14, CD16); the content of CD68+ macrophages in myocardium – by immunohistochemistry method. In both samples of blood, the content of galectin-3 in patients with ICMP was higher than in CHD patients without ICMP and the level of TGFβ was comparable between the groups. At ICMP, the concentration of MMP-9 in sinus blood was higher than that in CHD patients without ICMP in whom an excess of MCP-1 in the general blood flow was determined. The density of distribution of CD68+ cells in the myocardium in patients with ICMP was higher in the perianeurysmal zone than in the right atrium appendage. ICMP was characterized by a deficiency of non-classical monocytes, and CHD without ICMP – by an excess of intermediate cells in peripheral blood. Myocardium remodeling at ICMP is mediated by not so much TGFβ but intracardiac galectin-3, which determines the subpopulation composition of blood monocytes.

1 March 2019 in Tuberculosis
Verified
Journal Article
Closed access
OUOlga Urazova
Olga Urazova
ЕЧЕлена Чурина
Елена Чурина
RHR.R. Hasanova
R.R. Hasanova
VNV.V. Novitskiy
V.V. Novitskiy
VPV.S. Poletika
V.S. Poletika

15 November 2024 in Innovative Medicine of Kuban
Verified
Journal Article
Open access
PDF file
AAAshot Avagimyan
Ashot Avagimyan
MSMohammad Sheibani
Mohammad Sheibani
ATA. I. Trofimenko
A. I. Trofimenko
ELE. E. Lysov
E. E. Lysov
FKF. M. Khamidova
F. M. Khamidova
NSNizal Sarrafzadegan
Nizal Sarrafzadegan
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs with far-reaching protective effects in multiple organs. The protective potential of SGLT2i is much broader than that of the classical concept of glucose control and consists of an entire conglomerate of associated pleiotropic effects. This study aims to provide a descriptive review of the pleiotropic therapeutic potential of SGLT2i. The first part of the literature review examined the use of SGLT2i in cardiology and nephrology. The use of SGLT2i represents an innovative approach to improving patients’ quality of life and course of heart failure and chronic kidney disease, regardless of left ventricular ejection fraction and type 2 diabetes.